↓ Skip to main content

Dove Medical Press

Article Metrics

What is this page? Embed badge

A randomized Phase II trial of the tumor vascular disrupting agent CA4P (fosbretabulin tromethamine) with carboplatin, paclitaxel, and bevacizumab in advanced nonsquamous non-small-cell lung cancer

Overview of attention for article published in OncoTargets and therapy, November 2016
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • High Attention Score compared to outputs of the same age and source (81st percentile)

Mentioned by

patent
1 patent
reddit
1 Redditor

Citations

dimensions_citation
52 Dimensions

Readers on

mendeley
79 Mendeley
Summary Patents Reddit Dimensions citations
So far, Dimensions has found 52 publications that cite this research output.

52

The most recent citing publications are shown below. View all 52 publications that cite this research output on Dimensions.

This page is hosted by Altmetric on behalf of Dove Medical Press.